MétaCan
Menu
Back to cohort
Record W2095599995 · doi:10.1200/jco.2014.60.0734

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

2015· article· en· W2095599995 on OpenAlexfundno aff
Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan, Neyssa Marina, Gordana Jovic, Jane Hook, Mark Krailo, Mark C. Gebhardt, Zsuzsanna Pápai, James S. Meyer, Helen Nadel, R. Lor Randall, Claudia Deffenbaugh, Rajaram Nagarajan, Bernadette Brennan, G. Douglas Letson, Lisa A. Teot, Allen M. Goorin, Daniel Baumhoer, Leo Kager, Mathias Werner, Ching C. Lau, Kirsten Sundby Hall, Hans Gelderblom, Paul A. Meyers, Richard Görlick, Reinhard Windhager, K. Helmke, Mikael Eriksson, Peter M. Hoogerbrugge, Paula J. Schomberg, Per‐Ulf Tunn, Thomas Kühne, Heribert Jürgens, Henk van den Berg, Tom Böhling, Susan Picton, Marleen Renard, Peter Reichardt, Joachim Gerß, Trude Butterfaß‐Bahloul, Carol D. Morris, Pancras C.W. Hogendoorn, Beatrice Seddon, Gabriele Calaminus, Maria Michelagnoli, Catharina Dhooge, Matthew R. Sydes, Mark L. Bernstein

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldMedicine
TopicSarcoma Diagnosis and Treatment
Canadian institutionsnot available
FundersCilagChildren's Hospital of PittsburghUniversity College LondonNational Cancer InstituteUniversity of NottinghamHospital for Sick ChildrenDeutsche KrebshilfeUniversitair Medisch Centrum GroningenConnecticut Children's Medical CenterMedical Research CouncilChildren’s Oncology GroupLeids Universitair Medisch CentrumDalhousie UniversityCliniques Universitaires Saint-LucChildren's Hospitals and Clinics of MinnesotaBundesministerium für Bildung und ForschungRadboud UniversiteitChildren's Hospital ColoradoCleveland ClinicUniversiteit LeidenUniversität WienDeutsche ForschungsgemeinschaftEuropean Science FoundationUniversity of LeedsCancer Research UKCedars-Sinai Medical CenterUniversitätsspital BaselMemorial Sloan-Kettering Cancer CenterOchsner HealthSaint Luke's Health SystemEuropean CommissionNationwide Children's HospitalHelsingin YliopistoChildren's Healthcare of AtlantaVlaamse regeringNational Institute for Health and Care ResearchBC Children's HospitalArcadia FundMedizinische Universität WienCarilion ClinicNorges ForskningsrådPennsylvania State UniversitySundhed og Sygdom, Det Frie ForskningsrådCleveland Clinic FoundationCincinnati Children's Hospital Medical CenterChildren's National HospitalUniversity of PennsylvaniaChildren's Hospital of Philadelphia
KeywordsMedicineChemotherapySurgeryMethotrexateToxicityCisplatinOsteosarcomaDoxorubicinInternal medicineGastroenterologyUrologyPathology

Abstract

fetched live from OpenAlex

PURPOSE: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. PATIENTS AND METHODS: At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary). RESULTS: Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model. CONCLUSION: At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.064
GPT teacher head0.377
Teacher spread0.313 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations421
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicSarcoma Diagnosis and TreatmentFrench-language works237,207